Jump to navigation
Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance.
By 2030, the number of deaths attributed to lung cancer is expected to double for Latin American women and increase by 50% for men.
Newer treatment options, biomarker-based patient segmentation and the availability of biomarker-based treatment approaches have added to treatment complexity over the years.
The International Association for the Study of Lung Cancer (IASLC) announces a significant jump in the 2017 Impact Factor of the Journal of Thoracic Oncology (JTO) to 10.336, up from 6.595 in 2016.
The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic.
With this corner, I would like to draw your attention to our new strategic plan.
Join the only international association solely dedicated to lung cancer research and treatment.
The IASLC’s premier journal, emphasizing a multidisciplinary approach including original research (clinical trials and translational or basic research), reviews and opinion pieces.
Visit theWCLC Virtual Library